Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $41.5 million.

  • Arrowhead Pharmaceuticals' Change in Accured Expenses rose 76.24% to $33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.5 million, marking a year-over-year increase of 29.21%. This contributed to the annual value of $41.5 million for FY2025, which is 29.21% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Change in Accured Expenses of $41.5 million as of FY2025, which was up 29.21% from $32.1 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $41.5 million during FY2025, with a 5-year trough of -$15.0 million in FY2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $32.1 million (2024), whereas its average is $19.5 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Change in Accured Expenses skyrocketed by 378.73% in 2021, and later tumbled by 184.31% in 2023.
  • Arrowhead Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $9.5 million in 2021, then surged by 86.41% to $17.8 million in 2022, then plummeted by 184.31% to -$15.0 million in 2023, then spiked by 314.61% to $32.1 million in 2024, then climbed by 29.21% to $41.5 million in 2025.